세계의 정밀 정신의학 시장 보고서(2025년)
Precision Psychiatry Global Market Report 2025
상품코드 : 1889543
리서치사 : The Business Research Company
발행일 : On Demand Report
페이지 정보 : 영문 250 Pages
 라이선스 & 가격 (부가세 별도)
US $ 4,490 ₩ 6,532,000
PDF (Single User License) help
PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 6,490 ₩ 9,442,000
PDF (Site License) help
PDF 보고서를 동일 사업장의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 8,490 ₩ 12,352,000
PDF (Enterprise License) help
PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.


ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
ㅁ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.

한글목차

정밀 정신의학 시장 규모는 최근 급속히 확대되고 있습니다. 2024년 43억 4,000만 달러로 평가되었고, 2025년에는 49억 9,000만 달러에 달할 것으로 추정되며, CAGR 14.9%로 성장이 전망되고 있습니다. 지난 수년간의 성장은 디지털 헬스툴의 도입 확대, 정신의학 조사에 대한 투자 증가, 신경 영상 진단 시설의 확충, 맞춤형 치료에 대한 주목의 고조, 원격 모니터링 솔루션에 대한 수요 증가 등이 요인으로 생각됩니다.

정밀 정신의학 시장 규모는 향후 수년간 급속한 성장이 예상되고 있습니다. 2029년에는 85억 8,000만 달러에 달할 것으로 예측되며, CAGR 14.5%로 성장할 전망입니다. 예측 기간의 성장은 웨어러블 생체 센서의 보급 확대, 바이오테크놀러지 기업 및 의료 제공자 간 제휴 강화, 원격 정신의학 플랫폼 확충, 정밀 정신의학 스타트업에 대한 자금 증가, 정신 건강 평가에 있어서 유전자 검사의 활용 확대 등이 요인으로 됩니다. 예측 기간 주요 동향으로는 디지털 치료제의 기술적 진보, 신경영상 진단 및 바이오마커 분석의 발전, 개별화 정신치료의 연구개발에 대한 투자, 인지 평가 툴의 혁신, 원격 환자 모니터링 기술의 진전 등을 들 수 있습니다.

정신질환의 유병률 증가는 향후 수년간 정밀 정신의학 시장의 성장을 이끌 것으로 예측됩니다. 정신질환에는 기분, 사고 및 행동에 영향을 미치는 우울증, 불안장애, 쌍극성장애 등 다양한 상태가 포함됩니다. 정신질환 증가는 사회적, 경제적 및 환경적 압력에 의한 심리적 고통의 증대에 더해 진단률 향상에 기여하는 스크리닝의 개선과 공중의 의식 향상에 기인하고 있습니다. 정밀 정신의학은 진단 정확성 및 치료 결과를 향상시키는 데이터 중심의 개별화된 치료 전략을 제공함으로써 이러한 질병을 해결합니다. 예를 들어, 영국 공공 의료 서비스(NHS) 잉글랜드의 2023년 11월 발표에 따르면, 20-23세의 젊은층에서 정신질환의 추정 이환율은 2022년 18.7%에서 2023년에는 21.6%로 상승했습니다. 따라서 정신질환의 유병률 증가가 정밀 정신의학 시장의 확대를 견인하고 있습니다.

정밀 정신의학 시장의 주요 기업은 처방전 디지털 치료제와 같은 새로운 치료법을 개발하고 정신질환에 대한 개인화된 데이터 구동 치료를 실현하고 있습니다. 처방전 디지털 치료제는 임상가가 처방하는 소프트웨어 기반의 의료 개입으로, 모바일 단말을 통해 증거 기반 행동 치료 모듈을 제공하여 증상 관리 및 치료 준수를 향상시킵니다. 예를 들어, 2024년 8월에는 오오츠카 홀딩스의 미국 자회사인 정밀의료 기업 '오츠카 프레시전 헬스 주식회사'와 미국 디지털 치료기업 '클릭세라퓨틱스사'가 미국 식품의약품국(FDA)에 의해 큰 우울증 증상의 보조치료로 승인된 최초의 처방 디지털 치료제 'Rejoyn'을 발표했습니다. 본 제품은 감정적 얼굴 기억 과제 및 인지 행동 치료에 기반한 스킬 모듈을 조합한 6주간의 인지 및 감정 트레이닝 프로그램을 제공하여 디지털 처방, 환자 참여, 원격 모니터링을 지원합니다. 'Rejoyn' 출시는 정밀 정신의학에서 중요한 이정표이며, 디지털 치료제가 약물 치료를 보완하고 맞춤형 의료를 실현할 가능성을 보여줍니다. 또한 실시간 환자 데이터를 통합하여 치료 성과 및 복약 준수를 최적화하는 소프트웨어 기반 중재 방법의 보급을 뒷받침합니다.

목차

제1장 주요 요약

제2장 시장 특징

제3장 시장 동향 및 전략

제4장 시장 : 금리, 인플레이션, 지정학, 무역전쟁 및 관세, 그리고 코로나 및 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오

제5장 세계의 성장 분석 및 전략 분석 프레임워크

제6장 시장 세분화

제7장 지역별 및 국가별 분석

제8장 아시아태평양 시장

제9장 중국 시장

제10장 인도 시장

제11장 일본 시장

제12장 호주 시장

제13장 인도네시아 시장

제14장 한국 시장

제15장 서유럽 시장

제16장 영국 시장

제17장 독일 시장

제18장 프랑스 시장

제19장 이탈리아 시장

제20장 스페인 시장

제21장 동유럽 시장

제22장 러시아 시장

제23장 북미 시장

제24장 미국 시장

제25장 캐나다 시장

제26장 남미 시장

제27장 브라질 시장

제28장 중동 시장

제29장 아프리카 시장

제30장 경쟁 구도 및 기업 프로파일

제31장 기타 주요 기업 및 혁신 기업

제32장 세계 시장 경쟁 벤치마킹 및 대시보드

제33장 주요 인수합병(M&A)

제34장 최근 시장 동향

제35장 시장의 잠재력이 높은 국가, 부문 및 전략

제36장 부록

AJY
영문 목차

영문목차

Precision psychiatry is a data driven approach that integrates genetic, neurobiological, behavioral, and environmental information to understand individual disease mechanisms. Its primary goal is to improve diagnostic accuracy, guide personalized treatment, and enhance outcomes by minimizing trial and error in prescribing. It also supports preventive strategies through personalized risk assessment and continuous monitoring.

The main therapeutic approaches in precision psychiatry include pharmacotherapy, psychotherapy, neurostimulation, digital therapeutics, and combination therapies. Pharmacotherapy in precision psychiatry refers to the use of personalized medication plans based on an individual's genetic, biochemical, and clinical profile to manage mental health disorders. It employs various technologies such as genetic testing, biomarker analysis, brain imaging techniques, wearable devices, and artificial intelligence and machine learning solutions, and is indicated for conditions including depression, anxiety disorders, bipolar disorder, schizophrenia, and post traumatic stress disorder (PTSD). It is applied in diagnosis, treatment, and research, serving end users such as clinics, hospitals, research institutes, pharmaceutical companies, and home care settings.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The sudden escalation of U.S. tariffs and the consequent trade frictions in spring 2025 are severely impacting the healthcare sector, particularly in the supply of critical medical devices, diagnostic equipment, and pharmaceuticals. Hospitals and healthcare providers are facing higher costs for imported surgical instruments, imaging equipment, and consumables such as syringes and catheters, many of which have limited domestic alternatives. These increased costs are straining healthcare budgets, leading some providers to delay equipment upgrades or pass on expenses to patients. Additionally, tariffs on raw materials and components are disrupting the production of essential drugs and devices, causing supply chain bottlenecks. In response, the industry is diversifying sourcing strategies, boosting local manufacturing where possible, and advocating for tariff exemptions on life-saving medical products.

The precision psychiatry market research report is one of a series of new reports from The Business Research Company that provides precision psychiatry market statistics, including precision psychiatry industry global market size, regional shares, competitors with a precision psychiatry market share, detailed precision psychiatry market segments, market trends and opportunities, and any further data you may need to thrive in the precision psychiatry industry. This precision psychiatry market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The precision psychiatry market size has grown rapidly in recent years. It will grow from $4.34 billion in 2024 to $4.99 billion in 2025 at a compound annual growth rate (CAGR) of 14.9%. The growth in the historic period can be attributed to rising adoption of digital health tools, growing investment in psychiatric research, expansion of neuroimaging facilities, increasing focus on personalized treatment, and rising demand for remote monitoring solutions.

The precision psychiatry market size is expected to see rapid growth in the next few years. It will grow to $8.58 billion in 2029 at a compound annual growth rate (CAGR) of 14.5%. The growth in the forecast period can be attributed to increasing adoption of wearable biosensors, growing collaborations between biotech and healthcare providers, expansion of telepsychiatry platforms, rising funding for precision psychiatry startups, and increasing use of genetic testing in mental health assessment. Major trends in the forecast period include technological advancements in digital therapeutics, developments in neuroimaging and biomarker analysis, investment in research and development of personalized psychiatric treatments, innovation in cognitive assessment tools, and technological progress in remote patient monitoring.

The increasing prevalence of mental health disorders is expected to drive the growth of the precision psychiatry market in the coming years. Mental health disorders encompass a wide range of conditions, including depression, anxiety, and bipolar disorder, which impact mood, thinking, and behavior. The rise in mental health disorders is attributed to growing psychological distress from social, economic, and environmental pressures, along with improved screening and public awareness that contribute to higher diagnosis rates. Precision psychiatry addresses these disorders by providing data-driven, personalized treatment strategies that enhance diagnostic accuracy and therapeutic outcomes. For instance, in November 2023, according to NHS England, the UK based publicly funded national health authority, the rate of probable mental disorders among individuals aged 20 to 23 increased from 18.7 percent in 2022 to 21.6 percent in 2023. Therefore, the growing prevalence of mental health disorders is driving the expansion of the precision psychiatry market.

Major companies in the precision psychiatry market are developing new therapies such as prescription digital therapeutics to enable personalized, data-driven treatment for psychiatric conditions. A prescription digital therapeutic is a clinician-prescribed, software-based medical intervention that delivers evidence-based behavioral therapy modules through a mobile device to improve symptom management and treatment adherence. For example, in August 2024, Otsuka Precision Health Inc., a US based precision health subsidiary of Otsuka Holdings, and Click Therapeutics Inc., a US based digital therapeutics company, launched Rejoyn, the first prescription digital therapeutic cleared by the United States Food and Drug Administration (FDA) for adjunctive treatment of major depressive disorder symptoms. The product provides a six-week cognitive-emotional training program combining the emotional faces memory task with cognitive behavioral therapy based skill modules and supports digital prescribing, patient engagement, and remote monitoring. The launch of Rejoyn represents a key milestone in precision psychiatry, demonstrating how digital therapeutics can complement pharmacological treatments to deliver personalized care. It also supports broader adoption of software-based interventions that integrate real-time patient data to optimize treatment outcomes and adherence.

In January 2025, Johnson and Johnson, a US based pharmaceutical company, acquired Intra-Cellular Therapies Inc. for approximately $14.6 billion. Through this acquisition, Johnson and Johnson aims to expand its portfolio of innovative psychiatric therapies and leverage Intra-Cellular's expertise in mechanism-based drug development for central nervous system disorders. Intra-Cellular Therapies Inc. is a US based company focused on developing targeted neuropsychiatric therapies aligned with precision psychiatry.

Major companies operating in the precision psychiatry market are Johnson & Johnson, F. Hoffmann-La Roche Ltd, Pfizer Inc., AbbVie Inc., AstraZeneca plc, Novartis AG, Bristol-Myers Squibb Company, Thermo Fisher Scientific Inc., Eli Lilly and Company, Otsuka Pharmaceutical Company Limited, Laboratory Corporation of America Holdings, Quest Diagnostics Incorporated, Illumina Inc., ARUP Laboratories Inc., Sumitomo Dainippon Pharma Company Limited, QIAGEN N.V., Neurocrine Biosciences Inc., Tempus Labs Inc., Myriad Genetics Inc., MedGenome Labs Ltd., Genomind Inc., STALICLA SA

North America was the largest region in the precision psychiatry market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in precision psychiatry report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the precision psychiatry market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The precision psychiatry market includes revenues earned by entities through psychiatric assessment, personalized treatment planning, remote monitoring, data analytics, and clinical decision support. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Precision Psychiatry Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on precision psychiatry market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Where is the largest and fastest growing market for precision psychiatry ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The precision psychiatry market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.

Scope

Table of Contents

1. Executive Summary

2. Precision Psychiatry Market Characteristics

3. Precision Psychiatry Market Trends And Strategies

4. Precision Psychiatry Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

5. Global Precision Psychiatry Growth Analysis And Strategic Analysis Framework

6. Precision Psychiatry Market Segmentation

7. Precision Psychiatry Market Regional And Country Analysis

8. Asia-Pacific Precision Psychiatry Market

9. China Precision Psychiatry Market

10. India Precision Psychiatry Market

11. Japan Precision Psychiatry Market

12. Australia Precision Psychiatry Market

13. Indonesia Precision Psychiatry Market

14. South Korea Precision Psychiatry Market

15. Western Europe Precision Psychiatry Market

16. UK Precision Psychiatry Market

17. Germany Precision Psychiatry Market

18. France Precision Psychiatry Market

19. Italy Precision Psychiatry Market

20. Spain Precision Psychiatry Market

21. Eastern Europe Precision Psychiatry Market

22. Russia Precision Psychiatry Market

23. North America Precision Psychiatry Market

24. USA Precision Psychiatry Market

25. Canada Precision Psychiatry Market

26. South America Precision Psychiatry Market

27. Brazil Precision Psychiatry Market

28. Middle East Precision Psychiatry Market

29. Africa Precision Psychiatry Market

30. Precision Psychiatry Market Competitive Landscape And Company Profiles

31. Precision Psychiatry Market Other Major And Innovative Companies

32. Global Precision Psychiatry Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Precision Psychiatry Market

34. Recent Developments In The Precision Psychiatry Market

35. Precision Psychiatry Market High Potential Countries, Segments and Strategies

36. Appendix

(주)글로벌인포메이션 02-2025-2992 kr-info@giikorea.co.kr
ⓒ Copyright Global Information, Inc. All rights reserved.
PC버전 보기